The US Food and Drink Administration (FDA) has approved Calliditas Therapeutics' Tarpeyo (budesonide) delayed-release capsules to reduce the loss of kidney function in adults with IgAN.
Calliditas Therapeutics AB announced today (November 24) that its partner Everest Medicines has revealed that China's National Medical Products Administration (NMPA) has approved Nefecon.
Calliditas Therapeutics says it is optimistic about getting full marketing authorization for a drug to treat primary IgA nephropathy (IgAN) after submitting a request to the European Medicines Agency (EMA).